Extracellular-Signal Regulated Kinase: A Central Molecule Driving Epithelial–Mesenchymal Transition in Cancer
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Epithelial–mesenchymal transition (EMT) is a reversible cellular process, characterized by changes in gene expression and activation of proteins, favoring the trans-differentiation of the epithelial phenotype to a mesenchymal phenotype. This process increases cell migration and invasion of tumor cells, progression of the cell cycle, and resistance to apoptosis and chemotherapy, all of which support tumor progression. One of the signaling pathways involved in tumor progression is the MAPK pathway. Within this family, the ERK subfamily of proteins is known for its contributions to EMT. The ERK subfamily is divided into typical (ERK 1/2/5), and atypical (ERK 3/4/7/8) members. These kinases are overexpressed and hyperactive in various types of cancer. They regulate diverse cellular processes such as proliferation, migration, metastasis, resistance to chemotherapy, and EMT. In this context, in vitro and in vivo assays, as well as studies in human patients, have shown that ERK favors the expression, function, and subcellular relocalization of various proteins that regulate EMT, thus promoting tumor progression. In this review, we discuss the mechanistic roles of the ERK subfamily members in EMT and tumor progression in diverse biological systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196 · cited 2×
“Epithelial–mesenchymal transition (EMT) is a process of trans-differentiation by which epithelial cells change to a mesenchymal phenotype [1].”
BackgroundMolecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091 · cited 7×
“Furthermore, an enhanced expression of mesenchymal markers (N-cadherin, vimentin, fibronectin, α-SMA), the production of ECM-degrading enzymes, and ultimately the reorganization of the cytoskeleton and activation of transcription factors (TFs) that regulate EMT markers (Twist, Snail, Slug, ZEB, and β-catenin), are cri…”
BackgroundInfluentialActivation and function of the MAPKs and their substrates, the MAPK-activated protein kinases
Cargnello, M., & Roux, P. P. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00031-10 · Cited by 3,274
MAPK signal pathways in the regulation of cell proliferation in mammalian cells
ZHANG, W., & LIU, H. T. (2002) · Cell Research · doi:10.1038/sj.cr.7290105 · Cited by 2,845 · cited 1×
“Paxillin is a focal adhesion specific scaffold protein of the ERK1/2 cascade that can also be phosphorylated by this kinase [87,88].”
BackgroundA Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 1×
“Mutations in codon 12 (H-Ras), 13 (K-Ras), and 61 (N-Ras) are oncogenic as well [141,142].”
BackgroundRAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902
Epithelial Mesenchymal Transition in Tumor Metastasis
Mittal, V. (2018) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043854 · Cited by 1,528
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447 · cited 1×
“Some examples are the EGFR/HER2 inhibitors afatinib and neratinib [226,227], the BTK inhibitor ibrutinib [228], and osimertinib, a specific inhibitor of EGFR mutated in T790M [229].”
BackgroundRAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973 · cited 3×
“The most frequent hotspot mutations in cancer are G12 (83%), G13 (14%), and Q61 (2%) [138].”
BackgroundInfluentialThe RSK family of kinases: emerging roles in cellular signalling
Anjum, R., & Blenis, J. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2509 · Cited by 777 · cited 16×
“Sci. 2019, 20, 2885 8 of 32 cytosol, the active form of ERK can phosphorylate other kinases, phosphatases (PLA2, RSK) [23], and components of the cytoskeleton, mitochondria, endosomes/lysosomes, and Golgi [72].”
BackgroundInfluentialRas history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Morris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0070 · Cited by 676 · cited 2×
“Thus, both compounds may be considered type I and II ERK1/2 inhibitors, since they inhibit ERK1/2 catalytic activity and also impair the kinase’s phosphorylation and activation by MEK1/2 at the Thr-Glu-Tyr motif [214,216].”
BackgroundKeshet, Y., & Seger, R. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-795-2_1 · Cited by 642
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606 · cited 2×
“Interestingly, mutations in MEK1/2 have been found in patients with melanoma, lung, and colorectal cancer [27,151].”
BackgroundTargeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
Genomic and biochemical insights into the specificity of ETS transcription factors
Hollenhorst, P. C., McIntosh, L. P., & Graves, B. J. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.79.081507.103945 · Cited by 490 · cited 2×
“Among these, Elk1, a member of the TCF subfamily of the E-twenty-six (Ets)-domain TF, present both the D-peptide and F-site to enable its interaction with the CD-domain and (FSR) of ERK1/2 [61,91].”
BackgroundTumour cell survival signalling by the ERK1/2 pathway
Balmanno, K., & Cook, S. J. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.148 · Cited by 484
Shimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Smith, L. S., Gunn, S., Smetzer, L., Mays, T. A., Kaiser, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2381 · Cited by 431 · cited 3×
“Additionally, in melanoma, colorectal, and thyroid cancer, 18% of the patients had mutations in KRAS; of which 11% were comprised of the Gly12Ala and Gly12Cys mutations, 32% were Gly12Asp, 28% were Gly12Val, 12% were Gly12Ser, and 17% were Gly13Asp [136].”
BackgroundInfluentialAn essential function of the mitogen‐activated protein kinase Erk2 in mouse trophoblast development
Saba‐El‐Leil, M. K., Vella, F. D. J., Vernay, B., Voisin, L., Chen, L., Labrecque, N., Ang, S., & Meloche, S. (2003) · The EMBO Reports · doi:10.1038/sj.embor.embor939 · Cited by 366 · cited 1×
“For instance, while the erk1−/− mouse is viable and fertile, the erk2−/− model has embryonic lethality after the implantation stage [25].”
BackgroundSignalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions
BIONDI, R. M., & NEBREDA, A. R. (2003) · Biochemical Journal · doi:10.1042/bj20021641 · Cited by 334 · cited 2×
“The proteins of the RSK family are exclusively activated by ERK1/2, whereas MNK1 and MSK1 can also be activated by p38 [77].”
BackgroundJeong, W.-J., Ro, E. J., & Choi, K.-Y. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0049-y · Cited by 220
Young, A., Lou, D., & McCormick, F. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0231 · Cited by 211
Selectivity of Docking Sites in MAPK Kinases
Bardwell, A. J., Frankson, E., & Bardwell, L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900080200 · Cited by 127 · cited 3×
“The DRS is composed of a CD domain; two Asp residues in the CD domain and a hydrophobic groove interact with positively charged hydrophobic residues located in the kinase-interacting motif (KIM) or docking-peptide (D-peptide) [61,67,68].”
BackgroundWu, J., Ivanov, A. I., Fisher, P. B., & Fu, Z. (2016) · eLife · doi:10.7554/elife.10734 · Cited by 117 · cited 2×
“ERK1/2 regulates the expression of ZEB1 and ZEB2 through FRA1 and therefore also regulates EMT by decreasing the expression of E-cadherin and cytokeratin 19 and increasing the expression of N-cadherin, vimentin, and fibronectin [193].”
BackgroundStructure of ERK2 bound to PEA-15 reveals a mechanism for rapid release of activated MAPK
Mace, P. D., Wallez, Y., Egger, M. F., Dobaczewska, M. K., Robinson, H., Pasquale, E. B., & Riedl, S. J. (2013) · Nature Communications · doi:10.1038/ncomms2687 · Cited by 97 · cited 2×
“PEA-15 activates the ERK pathway in a RAS-dependent manner by binding solely to ERK2 [100,107].”
BackgroundXu, J., Pfarr, N., Endris, V, Mai, E. K., Md Hanafiah, N. H., Lehners, N., Penzel, R., Weichert, W., Ho, A. D., Schirmacher, P., et al. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.36 · Cited by 89 · cited 3×
“Likewise, in patients with multiple myeloma, the B-RAF Val600Glu mutation is also associated with an increase in ERK activity [152].”
BackgroundElsum, I. A., Martin, C., & Humbert, P. O. (2013) · Journal of Cell Science · doi:10.1242/jcs.129387 · Cited by 87 · cited 2×
“Additional evidence that establishes the role of ERK in EMT was obtained from the non-tumoral epithelial breast cells MCF10A, where the ectopic expression of the Scribble protein, which is essential for the maintenance of apical–basal polarity, decreased the phosphorylation state of MERK1/2 and ERK1/2 [177].”
BackgroundThe cell polarity regulator hScrib controls ERK activation through a KIM site-dependent interaction
Nagasaka, K., Pim, D., Massimi, P., Thomas, M., Tomaić, V, Subbaiah, V. K., Kranjec, C., Nakagawa, S., Yano, T., Taketani, Y., et al. (2010) · Oncogene · doi:10.1038/onc.2010.265 · Cited by 75
Quantitative Analysis of ERK2 Interactions with Substrate Proteins
Burkhard, K. A., Chen, F., & Shapiro, P. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.177899 · Cited by 62
Cited by
Exosomes: key players in cancer and potential therapeutic strategy
Dai, J., Su, Y., Zhong, S., Cong, L., Liu, B., Yang, J., Tao, Y., He, Z., Chen, C., & Jiang, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00261-0 · Cited by 1,186
Nanoparticle mediated alteration of EMT dynamics: an approach to modulate cancer therapeutics
Sen, P., Saha, M., & Ghosh, S. S. (2020) · Materials Advances · doi:10.1039/d0ma00455c · Cited by 21
MAPKs in the early steps of senescence implemEMTation
Anerillas, C., Altés, G., & Gorospe, M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1083401 · Cited by 13
“Importantly, the activity of ERK1/2 increases via ECM receptors and ECM ligands (Sheng et al., 2017; Ohkuro et al., 2018; Olea-Flores et al., 2019), and thus ERK1/2 activity could represent a key signaling node to adjust cell outcome to ECM status (Anerillas et al.”
Background
Metadata
- Authors
- Olea-Flores, M., Zuñiga-Eulogio, M. D., Mendoza-Catalán, M. A., Rodríguez-Ruiz, H. A., Castañeda-Saucedo, E., Ortuño-Pineda, C., Padilla-Benavides, T., & Navarro-Tito, N.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-06-13
- Volume
- 20
- Issue
- 12
- Pages
- 2885
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2951581858
- Cited by
- 146
- References
- 29
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.